Personalized Medicine · 2015 · 20 citations · 18 references
MedicineCommunity PharmacyPharmacologyClinical PharmacologyPharmacogeneticsPharmacogenomicsAntiplatelet TherapyCardiovascular PharmacologyClinical Implementation Of PharmacogeneticsClinical Implementation Of PharmacogenomicsMedication Therapy ManagementPharmacogenomics In CardiologyAntiplatelet DrugsCyp2c19 GenotypeCyp2c19 PharmacogeneticsCyp2c19-guided Antiplatelet TherapyMyocardial Infarction PharmacogenomicsMyocardial Infarction PharmacotherapyPercutaneous Coronary Intervention CarePost-myocardial Infarction Pharmacotherapy
AIM: The purpose of this study was to pilot a multisite, proof-of-concept model where community pharmacists could engage patients and physicians to provide pharmacogenetic (PGt) testing and clinical decision support. PATIENTS & METHODS: Patients with history of acute myocardial infarction and percutaneous coronary intervention with no prior history of CYP2C19 testing. RESULTS: Four community pharmacies provided pharmacogenetic testing and medication therapy management services to 30 patients, resulting in eight recommendations for antiplatelet therapy adjustment. CONCLUSION: Pharmacists involved in the study were able to facilitate antiplatelet therapy adjustments based on PGt data regardless of baseline antiplatelet drug selection. Whereas prior literature largely revolved around PGt management in the inpatient setting, this project supports the involvement of the community pharmacist in making PGt-based recommendations.
18
Marco Valgimigli, Marco Borghesi, Matteo Tebaldi et al. · European Heart Journal · 2013 · 107 citations